Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19419 | 0.91 | KDM4E (0.54) | EBPSIGMAR1HRH3KDM4E | |
| SCHEMBL5536172 | 0.89 | MAOA (0.50) | — | |
| SCHEMBL5542660 | 0.87 | MAOA (0.52) | — | |
| SCHEMBL5542033 | 0.87 | MAOA (0.52) | — | |
| SCHEMBL10372509 | 0.87 | BCHE (0.45) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL9706125 | 0.86 | EBP (0.72) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL25288225 | 0.84 | EBP (0.43) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL2181408 | 0.83 | DRD2 (0.44) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL2181780 | 0.82 | DRD2 (0.46) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL11522619 | 0.80 | EBP (0.36) | EBPSIGMAR1CYP2D6HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102741256-A | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM IND CO LTD | 2012-10-17 | — | — | CN | claimed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | claimed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | claimed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | claimed |
| WO-2010014798-A2 | PYRIMIDOTRIAZINEDIONES AND PYRIMIDOPYRIMIDINEDIONES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-04 | — | — | WO | claimed |
| US-7452914-B2 | Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-18 | — | — | US | claimed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | claimed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | claimed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | claimed |
| JP-2007521323-A | — | — | 2007-08-02 | — | — | JP | claimed |
| US-5665780-A | DEACTIVATING P-GLYCOPROTEIN PUMP IN TUMORS; CANCER TREATMENT | MERRELL PHARMACEUTICALS INC. (US) | 1997-09-09 | — | — | US | claimed |
| EP-0624090-B1 | REVERSAL OF MULTI-DRUG RESISTANCE BY TETRAARYLETHYLENES | MERRELL PHARMA INC (US) | 1996-09-18 | — | — | EP | claimed |
| EP-0624090-A1 | REVERSAL OF MULTI-DRUG RESISTANCE BY TETRAARYLETHYLENES. | MERRELL DOW PHARMA (US) | 1994-11-17 | — | — | EP | claimed |
| WO-1993015733-A1 | REVERSAL OF MULTI-DRUG RESISTANCE BY TETRAARYLETHYLENES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-19 | — | — | WO | claimed |
| US-5231105-A | Ethylamine derivatives and antihypertensives containing the same | AJINOMOTO CO., INC. (JP) | 1993-07-27 | — | — | US | claimed |
| US-4716168-A | STIMULANTS OF IMMUNE RESPONSE | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1987-12-29 | — | — | US | claimed |
| EP-0093515-B1 | TRICYCLIC TRIAZINO COMPOUNDS, THEIR USE AND FORMULATION AS PHARMACEUTICALS AND PROCESSES FOR THEIR PRODUCTION | FISONS plc (GB) | 1987-01-21 | — | — | EP | claimed |
| EP-0187705-A2 | Imidazo(4,5-f)quinolines useful as immunomodulating agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1986-07-16 | — | — | EP | claimed |
| US-4499269-A | IMMUNO-REGULANT, SKIN DISORDERS, ANTITUMOR AGENTS | FISONS PLC (GB) | 1985-02-12 | — | — | US | claimed |
| EP-0093515-A1 | Tricyclic triazino compounds, their use and formulation as pharmaceuticals and processes for their production | FISONS plc (GB) | 1983-11-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | EBP 1026/4885SIGMAR1 420/4885CYP2D6 998/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | EBP 3660/4885SIGMAR1 4519/4885CYP2D6 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.